Axis Biotec Brasil is set to begin construction work on a new biopharmaceutical laboratory and pilot production facility in Rio de Janeiro.

The laboratory and manufacturing facility will support the production of key biosimilar and bio-better protein drugs for the Brazilian market through a joint venture (JV) between Axis Biotec and Canadian biotech firm PlantForm.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Known as PlantPraxis, the new JV will first manufacture a biosimilar version of adalimumab (Humira) for rheumatoid arthritis and other inflammatory disorders.

Axis Biotec Brasil founder and CEO Eduardo Cruz said: “We’re very pleased to be moving forward with this exciting initiative, which will benefit many of the estimated 13 million people in Brazil who require treatment with monoclonal antibody drugs.

"Brazil is the seventh largest market for pharmaceuticals in the world and construction of the new PlantPraxis facility advances PlantForm’s global strategy for biosimilar drug development."

“We look forward to working with the PlantForm team to continue advancing our plans to make affordable biopharmaceuticals available to millions of Brazilians.”

See Also:

The construction of the lab and facility will be supported by funding received from Brazilian Funding Agency for Studies and Projects (Finep), which provided a $1m grant to Silvestre Labs, part of the Axis Biotec Brasil group of companies.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

PlantForm president and CEO Don Stewart said: “Brazil is the seventh largest market for pharmaceuticals in the world and construction of the new PlantPraxis facility advances PlantForm’s global strategy for biosimilar drug development.”

Construction work on the new facility is expected to be completed by the end of this year and slated to be operational next year.

It will initially focus on the development of adalimumab with several additional biological targets in the pipeline.